Healios KK HLOSF
Trading Information
- Previous Close Price
- $1.80
- Day Range
- $1.80–1.80
- 52-Week Range
- $1.80–4.45
- Bid/Ask
- $1.60 / $501.85
- Shares Outstanding
- 135.00M
- Market Cap
- $243.00M
- Volume/Avg
- 800 / 670
Key Statistics
- Price/Earnings (Normalized)
- 267.25
- Price/Sales
- 591.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 102
- Website
- https://www.healios.co.jp
Valuation
|
Metric
|
HLOSF
|
|---|---|
Price/Earnings (Normalized) | 267.25 |
Price/Book Value | 5.21 |
Price/Sales | 591.02 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HLOSF
|
|---|---|
Quick Ratio | 1.95 |
Current Ratio | 2.05 |
Interest Coverage | — |
Quick Ratio
HLOSF
Profitability
|
Metric
|
HLOSF
|
|---|---|
Return on Assets (Normalized) | 1.08% |
Return on Equity (Normalized) | 4.41% |
Return on Invested Capital (Normalized) | −39.88% |
Return on Assets
HLOSF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@fsSk< | LOCK|y?Fq | $126B | |||
| Moderna Inc
MRNA
| LOCK|M!RK<%k | LOCK|<& | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>l!&$W | LOCK|jJ!s | $80B | |||
| argenx SE ADR
ARGX
| LOCK|!>?&ht | LOCK|$p | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&F#XZ< | LOCK|fjG | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|P>&&hJ | LOCK|hHgc< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$?R#!mb# | LOCK|vc&^G | $26B | |||
| Incyte Corp
INCY
| LOCK|%cl%Zj | LOCK|X$v | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$Q&g>FF | LOCK|>^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Y?<%fc! | LOCK|K#@ | $14B |
United States